Background: Chlorhexidine gluconate (CHG) is a topical antiseptic widely utilized for daily bathing in pediatric and adult populations and has been shown to be effective in reducing healthcare-associated infections (HAIs). However, the Centers for Disease Control (CDC) recommends using it with caution in patients less than 2 months of age. However, as HAIs remain a significant problem in this patient population, a study is ongoing at our institution addressing these concerns. The clinical chemistry team was recruited to help characterize CHG levels for this population. Preliminary validation results are reported here. Methods: A LC-MS/MS method was developed to quantitate CHG plasma levels. Linearity was determined from linear regression analysis (n = 7) of plasma levels spiked at 500ng/mL and diluted to 5 ng/mL. Precision was assessed by replicate measurement (n = 5) of CHG in spiked patient pools across the concentration range of 10 to 500 ng/mL. Adult, medical intensive care unit (MICU), and neonatal intensive care unit (NICU) patient pools were created (n = 3) from discarded clinical specimens. Matrix effect was measured by spiking in CHG in the pool and recovery was subsequently measured at 5, 20 and 100 ng/mL. Results: The calibration curve showed excellent correlation between the concentration and signal response (r = .97). Preliminary assay imprecision (%CV) was assessed at CHG concentrations of 500, 200, 100, 20, and 10 ng/ mL. The mean coefficient of variation (%CV) using the LC-MS/MS method at 500, 200, 100, 20, and 10 ng/mL were 2.9%, 4.9%, 4.3%, 17.4%, and 59.4%, respectively. Randomly selected clinically discarded specimens also revealed high background CHG exposure (>50 ng/mL). Baseline adult, MICU, and NICU pools showed >20 ng/ mL CHG levels. The adult, MICU, and NICU pools showed comparable recovery across the different types of pools. Average recovery (%) ranged 37%-41%, 31%-37%, and 80%-115% at 5, 20, and 100 ng/mL, respectively. Conclusion: We have developed a LC-MS/MS method that allows us to quantitate chlorhexidine in patients younger than 2 months. We also show that detectable levels were common in neonates less than 2 months old.
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Validation of Thromboxane A2 Analogue U46619 in Whole Blood Platelet Aggregation to Diagnose Platelet Disorders
Xi Zhang, Morayma Reyes-Gil; Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY Thromboxane A2 analogue U46619 is conventionally used in platelet-rich plasma aggregometry (optical method) to diagnose platelet disorders. However, a significant proportion of the normal population is nonsensitive to U46619 (~10-20%). Noteworthy, a protocol for the use of U46619 in whole blood aggregometry (impedance method) is yet to be established and published. Herein we aimed to validate the use of U46619 in whole blood aggregometry, and improve its sensitive and specificity to detect secretion problems. Serial doses of U46619 (calculated based on hematocrit adjustment) where tested in whole blood from normal donors. After an optimal concentration was chosen, 45 normal donor samples were tested to establish a reference range. Also, we tested if the addition of the chemiluminescence reagents (luciferase and luciferin) to detect ATP secretion improves the sensitivity and specificity. More than 100 cases were analyzed using U46619 as part of a panel including other common platelet agonists such as ADP, collagen, arachidonic acid, thrombin, and ristocetin. The addition of the chemiluminescence reagents significantly improved the platelet aggregation response in normal donors: in the cohort without chemiluminescence reagents, approximately 10% were nonsensitive (no aggregation detected), whereas in the cohort with chemiluminescence reagents the average aggregation response (as measure in ohms) doubled. Therefore, the specificity is 98%, as determined by the number of cases diagnosed as "normal" or non-clinically significant but showed abnormal platelet aggregation response to U46619. The sensitivity was also high, 92%, as determined by the number cases with abnormal response that were diagnosed with a platelet disorder using further confirmatory testing (platelet electron microscopy or molecular testing). In summary, U46169 in whole blood aggregometry is highly sensitive and specific for detection of platelet disorders, in particular storage pool disorders. Furthermore, U46619 is extremely useful to differentiate aspirin-like defects from secretion problems. Finally, we will present examples of U46619-induced platelet aggregation and ATP secretion in a series of common platelet disorders, including Bernard-Soulier, Glanzmann thrombasthenia, aspirin-like defects, and storage pool disorders, as well as other rare platelet disorders such as Rett syndrome, Paris-Trousseau syndrome, and Noonan syndrome. 
Background:
Worldwide, approximately 50 million people live with epilepsy, a quarter of which are treated with antiepileptic drugs (AEDs). Therapeutic drug monitoring (TDM) of AEDs is often necessary to assess therapeutic compliance, potential drug-drug interactions, and pharmacokinetic inter-and intravariability secondary to significant differences in excretion and metabolism. TDM is necessary to minimize the destructive toxicities of AEDs including hematopoietic dysfunction, pruritus, rash, Steven-Johnson syndrome, anxiety, agitation, suicidal ideation, liver failure, gastrointestinal issues, and neurologic dysfunction. Tandem mass spectrometry with stable isotope internal standards is the gold standard for the measurement of AEDs. Here, we present a rapid ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the simultaneous measurement of gabapentin, lamotrigine, levetiracetam, monohydroxy derivative (MHD) of oxcarbazepine (the main, active oxcarbazepine metabolite, also known as licarbazepine), and zonisamide in serum. Methods: For analysis, 20 µL serum samples were added to acetonitrile in the presence of deuterated internal standards for protein precipitation. After centrifugation, 10 µL of supernatant was added to 90 µL of water. Ten µL of this solution was injected into a C18 column for reversed phase UPLC chromatographic separation. Quantification of analytes was accomplished using positive-mode electrospray ionization and collision-induced dissociation MS. Total run time was 3 minutes. Assay parameters were evaluated according to Food and Drug Administration (FDA) bioanalytical guidelines. Results: To guide our assay development, we evaluated the range of AED levels for our patient population from lab results assayed at a reference laboratory. Over the course of one year, 1,825 total samples were assayed. One levetiracetam drug level was greater than 100 ug/mL, and the lower limit of quantification (LLOQ) for all drugs analyzed ranged between 2 ug/mL and 0.2 ug/mL. Therefore, an assay range of 0.1 ug/mL to 100 ig/mL was chosen for all analytes and was linear (r2 > .999) from 0.1 ug/mL to 100 ug/mL. This assay demonstrated acceptable accuracy and precision (%DEV <20% and %CV <20% for the LLOQ, %DEV <15% and %CV <15% at all other levels tested), linearity across the reportable range (r2 > .999, slopes ranging 0.968-1.062), carryover, stability under relevant storage conditions, matrix effects, recovery, and extraction and processing efficiency in accordance with FDA guidelines. Additionally, a cross-comparison with a reference laboratory using a similar methodology was performed.
Conclusions: A rapid, high-throughput, and robust UPLC-MS/MS method for monitoring multiple antiepileptics was developed and validated to address the clinical needs of our patient population. 
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UHRF2 Is Expressed in Human Diffuse
University of Minnesota Medical School, Minneapolis
Objective: Diffuse large B cell lymphoma (DLBCL) is a neoplasm of large B lymphocytes with a diffuse growth pattern. Though morphologically homogeneous, there is heterogeneity in DLBCL biology. The World Health Organization (WHO) has divided DLBCL into different prognostic categories based on morphology, genetics, immunophenotype, and clinical presentation. Ubiquitinlike with PHD and ring finger domains 2 (UHRF2) protein is involved in cell-cycle regulation and is an important transcriptional co-activator of E2F1-induced cell death genes. Prior studies have suggested that UHRF2 may interact with p53. In previous studies, we demonstrated that UHRF2 varies in expression and localization in diverse human cancers, including one case of non-Hodgkin lymphoma. In the current study, our major objectives were to characterize the expression of UHRF2 in human DLBCL and correlate its expression patterns with pathologic and clinical features; the long-term outcome is to understand whether UHRF2 is an important regulator of DLBCL biology. Methods: After receiving an internal review board waiver, we performed a natural language search of the pathology database to identify nodal, primarily de novo, adult human DLBCL cases diagnosed at the University of Minnesota between 2003 and 2016. Hematoxylin and eosin (H&E) slides were reviewed by two authors (MF and ML) to verify the diagnosis and evaluate for specimen adequacy. After excluding needle core biopsies, 37 samples (36 patients) were included to construct a DLBCL tissue microarray (TMA). Clinical data were collected through electronic medical record searches. Control tissues from spleen, thymus, bowel, tonsil, and appendix, as well as the 37 samples were spotted randomly in triplicate to construct a 128-spot TMA. TMA slices were stained with H&E and CD3, Ki67, PAX-5, p53, and UHRF2 immunostains. All samples were evaluated by light microscopy and scored by two authors (MF and ML). Results: Cases represented 18 men and 18 women, with a mean age at diagnosis of 64 (range 21-84). All cases of DLBCL expressed UHRF2; however, there was variability in UHRF2 expression. We categorized cases into
